cefamandole

Trade name: mandol

Small moleculeapproved

Approved

Sep 27, 1978

Cefamandole (also known as cephamandole) is a broad-spectrum cephalosporin antibiotic. The clinically used form of cefamandole is an ester form, cefamandole nafate, a prodrug. Cefamandole is no longer available in USA, but it has prescription in UK. Cefamandole under brand name mandol is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms such as: lower respiratory infections, including pneumonia, caused by S. pneumoniae. So as urinary tract infections caused by E. coli, Proteus spp.; peritonitis caused by E. coli and Enterobacter spp. Septicemia caused by E. coli; skin and skin structure infections caused by S. aureus; bone and joint infections caused by S. aureus (penicillinase- and non-penicillinase-producing). Like all beta-lactam antibiotics, cefamandole binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Bacterial cell wall autolytic enzymes such as autolysins then mediate cell lysis; it is possible that cefamandole interferes with an autolysin inhibitor. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1970s

  1. Sep 27, 1978

    Eli Lilly — Earliest FDA Approval

  2. Sep 27, 1978

    Eli Lilly — NDA Organization

1980s

  1. Sep 10, 1985

    Eli Lilly — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewSep 27, 1978

Chemistry & pharmacology

Loading structure…

SMILES

Cn1nnnc1SCC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1
Mol. weight
490.52 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Prodrug

Sources

Also known as

  • 106223
  • (6r,7r)-7-{[(2r)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • (6r,7r)-7-{[(2r)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
  • (6r,7r)-7-(r)-mandelamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid
  • (6r,7r)-7-(r)-mandelamido-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid
  • cefadole
  • cefadole
  • cefadole
  • cefamandol
  • cefamandol
  • cefamandol
  • cefamandole
  • cefamandole
  • cefamandole
  • cefamandole
  • cefamandole
  • cefamandole
  • cefamandole
  • cefamandole
  • cefamandole
  • cefamandole formate sodium
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate
  • cefamandole nafate, monosodium salt, 14c-labeled, (6r-(6alpha,7beta,(r*)))-isomer
  • cefamandole nafate, monosodium salt, (6r-(6alpha,7beta(r*)))-isomer
  • cefamandole nafate sodium
  • cefamandole nafate sodium
  • cefamandolum
  • cefamandolum
  • cephadole
  • cephadole
  • cephadole
  • cephamandole
  • cephamandole
  • cephamandole
  • cephamandole
  • cephamandole nafate
  • cephamandole nafate
  • cephamandole nafate
  • compound 83405
  • compound 83405
  • kefadol
  • kefandol
  • lampomandol
  • l-cefamandole
  • l-cefamandole
  • mandol
  • mandol
  • mandol
  • mandol
  • neocefal

Organizations

Marketing (3)

OrganizationOrg typeRelationshipDate
Eli LillyFor profitSYNSep 27, 1978
Eli LillyFor profitNDASep 27, 1978
Eli LillyFor profitMKTGSep 10, 1985